Myomo Stock News

Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt

Myomo, Inc. (NYSE:MYO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Ch

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, MA / ACCESSWIRE / October 5, 2022 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi

Myomo, Inc. (NYSE:MYO ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 6.67% and 4.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi

Myomo, Inc. (NYSE:MYO ) Q1 2022 Results Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kim Golodetz - IR, LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henr

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 24.07% and 35.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals KALA +20%. Natera NTRA +17%. Sunshine Biopharma SBFM -32%. Myomo (MYO) -28%.

Myomo press release (MYO): Q4 GAAP EPS of -$0.52 misses by $0.03.Revenue of $4.0M (+5.5% Y/Y) beats by $1.01M.

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2021. Financial and operational highlights for the fourth quarter of 2021 include the following (all comparisons are with the fourth quarter of 2020, unless otherwise noted): Revenue w

Myomo, Inc. (MYO) CEO Paul Gudonis on Q4 2021 Results - Earnings Call Transcript